{"nctId":"NCT00710385","briefTitle":"Abuse Liability of Suboxone Versus Subutex","startDateStruct":{"date":"2007-09"},"conditions":["Opioid-related Disorders"],"count":19,"armGroups":[{"label":"Heroin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Heroin"]},{"label":"Naloxone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Naloxone"]},{"label":"Low Bup Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Low Bup Dose"]},{"label":"Low Bup/Nal Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Low Bup/Nal Dose"]},{"label":"High Bup Dose","type":"EXPERIMENTAL","interventionNames":["Drug: High Bup Dose"]},{"label":"High Bup/Nal Dose","type":"EXPERIMENTAL","interventionNames":["Drug: High Bup/Nal Dose"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (PCB)"]}],"interventions":[{"name":"Heroin","otherNames":["Diacetylmorphine"]},{"name":"Naloxone","otherNames":["Naloxone Hydrochloride (HCl)"]},{"name":"Low Bup Dose","otherNames":["Subutex"]},{"name":"High Bup Dose","otherNames":["Subutex"]},{"name":"Low Bup/Nal Dose","otherNames":["Suboxone"]},{"name":"High Bup/Nal Dose","otherNames":["Suboxone"]},{"name":"Placebo (PCB)","otherNames":["0 mg"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnostic and Statistical Manual (DSM) IV criteria for heroin dependence\n* No major mood, psychotic, or anxiety disorder\n* Physically healthy\n* Able to perform study procedures\n* 21-45 years of age\n* Normal body weight\n* Current use of i.v. opioids in amounts and/or frequencies that meet or exceed those used in the proposed study (1-2 bags of heroin per occasion at least twice per day)\n* Self-administer at least 4 mg i.v. buprenorphine above placebo levels during the dose run up phase\n\nExclusion Criteria:\n\n* DSM IV criteria for dependence on drugs other than opioids, nicotine or caffeine\n* Participants requesting treatment\n* Participants on parole or probation\n* Pregnancy or lactation\n* Birth, miscarriage or abortion within 6 months\n* Current or recent history of significant violent behavior\n* Current major Axis I psychopathology, other than opioid dependence (e.g., mood disorder with functional impairment or suicide risk, schizophrenia), that might interfere with ability to participate in the study\n* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 times the upper limit of normal\n* Significant suicide risk\n* Current chronic pain\n* Sensitivity, allergy, or contraindication to opioids\n* Current or recent (past 30 days) physical dependence on or treatment with methadone, buprenorphine, or the buprenorphine/naloxone combination","healthyVolunteers":true,"sex":"ALL","minimumAge":"21 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Drug's Breakpoint","description":"Measure of a drug's reinforcing effects. The \"Breakpoint\" is the point at which the participant stop performing an operant task (clicks on a mouse) in order to received the drug. Therefore, the reported breakpoint is the total amount of work the participant was willing to perform to receive the dose being tested","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1200","spread":"200"},{"groupId":"OG001","value":"10","spread":"10"},{"groupId":"OG002","value":"1100","spread":"180"},{"groupId":"OG003","value":"1200","spread":"190"},{"groupId":"OG004","value":"300","spread":"100"},{"groupId":"OG005","value":"750","spread":"175"},{"groupId":"OG006","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Drug \"Liking\"","description":"Participant's subjective ratings of how much they \"Like\" the dose they just received on a scale of 0 -100.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5","spread":"5"},{"groupId":"OG001","value":"3","spread":"2.7"},{"groupId":"OG002","value":"29.8","spread":"4"},{"groupId":"OG003","value":"42.5","spread":"5"},{"groupId":"OG004","value":"10.5","spread":"2.4"},{"groupId":"OG005","value":"27","spread":"4"},{"groupId":"OG006","value":"1","spread":".6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":17},"commonTop":["Mild Opioid Withdrawal","urticaria","vomiting","dizziness","chest discomfort"]}}}